___

• Mankoc-Ramus S, Kumse T, Globocnik Petrovic M, Petrovic D, Cilensek I. SNP rs 2073618 of the osteoprotegerin gene is associated with diabetic retinopathy in Slovenian patients with type 2 diabetes. Bio Med Res Int 2013;2013:364073.
• Perez de Ciriza C, Lawrie A, Varo N. Influence of preanalytical and analytical factors on osteoprotegerin measurments. Clin Biochem 2014:47:1279-85.
• Michowitz Y, Goldstem E, Roth A, Afek A, Abashidze, Ben Gal Y, et al. The involvement of tumor necrosis factor related apoptosis-inducing ligand (TRAIL) in atherosclerosis. J Am Coll Cardiol 2005;45:1018-24.
• Seccihiero P, Candido R, Corallini F, Zacchigna S, Toffoli B, Rimondi E, et al. Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation 2006;114:1522-30.
• Kim HH, Shin HS, Kwak HJ, Ahn KY, Kim JH, Lee MS, et al. RANKL regulates endothelial cell survival through the phosphatidylinositol 3-kinase/Akt signal transduction pathway. FASEB J 2003;17:2163-5.
• Kim YM, Kim YM, Lee YM, Kim HS, Kim JD, Choi Y, et al. TNF-related activationinduced cytokine (TRANCE) induces angiogenesis through the activation of Src and phospholipase C (PLC) in human endothelial cells. J Biol Chem 2002;277:6799-805.
• Min JK, Kim YM, Kim YM, Kim EC, Gho YS, Kang IJ, et al. Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. J Biol Chem 2003;278:39548-57.
• Shaker OG, El-Shehaby A, Nabih M. Possible role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as markers of plaque instability in coronary artery disease. Angiology 2010;61:756-62.
• Safar ME, ‎Edward D. Frohlich. Large Arteries and Cardiovascular Risk. Atherosclerosis, Press; 2007:44:117-24.
• Lakatta EG, Mitchell JH, Pomerance A, Rowe GG. Human aging: changes in structure and function. J Am Coll Cardiol 1987;(2 Suppl A)10:42-7.
• Proudfoot D, Shanahan CM. Biology of calcification in vascular cells: intima versus media. Herz 2001;26:245-51.
• Tintut Y, Alfonso Z, Saini T, Radcliff K, Watson K, Boström K, et al. Multilineage potential of cells from the artery wall. Circulation 2003;108:2505-10.
• Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004;24:1161-70.
• Hosbond SE, Poulsen TS, Diederichsen AC, Nybo M, Rasmussen LM, Mickley H. Osteoprotegerin as a marker of atherosclerosis: A systemic update. Scand Cardiovasc J 2012;46:203-11.
• Mori K, Jono S, Emoto M, Kawagishi T, Yasumoto H, Konishi T, et al. Effects of pravastatin on serum osteoprotegerin levels in patients with hypercholesterolemia and type 2 diabetes. Angiology 2010;61:86-91.
• Nezami N, Safa J, Eftekhar-Sadat AT, Salari B, Ghorashi S, Sakhaee K, et al. Lovastatin raises serum osteoprotegerin level in people with type 2 diabetic nephropathy. Clin Biochem 2010;43:1294-9.
• Nellemann B, Gormsen LC, Dollerup J, Schmitz O, Mogensen CE, Rasmussen LM, et al. Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. Diabetes Care 2007;30:3122-4.
• Bernardi S, Fabris B, Thomas M, Toffoli B, Tikellis C, Candido R, et al. Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. Mol Cell Endocrinol 2014;394:13-20.
• Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-808.
• Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008;9:367-77.
• Carr DB, Utzschneider KM, Hull RL,Kodama K, Retzlaff BM, Brunzell JD, et al. Intra- abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004;53:2087-94.
• Kahn R, Buse J, Ferrannini E, Stern M; American Diabetes Association and European Association for the Study of Diabetes. The Metabolic syndrome: Time for a critical appraisal: Joint Statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289-304.
• Jorgensen GM, Vind B, Nybo M, Rasmussen LM, Hojlund K. Acute hyperinsulinemia decreases plasma osteoprotegerin with diminished effect in type 2 diabetes and obesity. Eur J Endocrinol 2009;161:95-101.
• Knudsen ST, Jeppesen P, Poulsen PL, Andersen NH, Bek T, Schmitz O, et al. Plasma concentrations of osteoprotegerin during normo- and hyperglycaemic clamping. Scand J Clin Lab Invest 2007;67:135-42.
• Ugur Altun B, Altun A. Circulating Leptin and Osteoprotegerin Levels Affect Insulin Resistance in Healthy Premenopausal Obese Women. Arch Med Res 2007;38:891-6.
• Ugur Altun B, Altun A, Gerenli M, Tugrul A. The relationship between insulin resistance assessed by HOMA-IR and serum osteoprotegerin levels in obesity. Diabetes Res Clin Pract 2005;68:217-22.
• Gannage-Yared MH, Fares F, Semaan M, Khalife S, Jambart S. Circulation osteoprotegerin is correlated with lipid profile, insulin sensitivity adiponectin and sex steroids in an ageing male population. Clin Endocrinol (Oxf) 2006;64:652-8.
• Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 2001;276;20659-72.
• Seccihero P, Corrallini F, Pandolfi A, Consoli A, Candido R, Fabris B, et al. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to cell dysfunction. Am J Pathol 2006;169:2236-44.
• Grauslund J, Rasmussen LM, Green A, Sjolie A. Does osteoprotegerin relate to microvascular complications in long-term type 1 diabetes? Scand J Clin Lab Invest 2010;70:188-93.
• Avignon A, Sultan A, Piot C, Mariano-Goulart D, Thuan Dit Dieudonne JF, Cristol JP, et al. Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care 2007;30:2934-9.
• Avignon A, Sultan A, Piot C, Elaerts S, Cristol JP, Dupuy AM. Osteoprotegerin is associated with silent coronary artery disease in high risk but asymptomatic type 2 diabetic patients. Diabetes Care 2005;28:2176-80.
• Galluzzi F, Stagi S, Salti R, Toni S, Piscitelli E, Simonini G, et al. Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status. Eur J Endocrinol 2005;153:879-85.
• Olesen P, Ledet T, Rasmussen LM. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia 2005;48:561-8.
• Oh ES, Rhee EJ, Oh KW, Lee WY, Baek KH, Yoon KH, et al. Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum-total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women. Metabolism 2005;54:49-54.
• Akyuz A, Oran M, Alpsoy S, Mutlu LC, Degirmenci H, Kucukyalın V, et al. Association between drug-resistant hypertension and increased osteoprotegerin levels in hypertensive male patients with non-obstructive sleep apnea. Acta Medica Mediterr 2014;30:1381-6.
• Tomiyama H, Yamashina A. Non-invasive vascular function tests: Their pathophysiological background and clinical application. Circ J 2010;74:24-33.
• Wang JH, Lee CJ, Chen ML, Yang CF, Chen YC, Hsu BG. Association of serum osteoprotegerin levels with carotid-femoral pulse wave velocity in hypertensive patients. J Clin Hypertens (Greenwich) 2014;16:301-8.
• Moran CS, McCann M, Karan M, Norman P, Ketheesan N, Golledge J. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation 2005;111:3119-25.
• Shimizu H, Nakagami H, Osako MK, Hanayama R, Kunugiza Y, Kizawa T, et al. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J 2008;22:2465-75.
• Asaba Y, Ito M, Fumoto T, Watanabe K, Fukuhara R, Takeshita S, et al. Activation of renin-angiotensin system induces osteoporosis independently of hypertension. J Bone Miner Res 2009;24:241-50.
• Weiss RM, Lund DD, Chu Y, Brooks RM, Zimmerman KA, El Accaoui RE, et al. Osteoprotegerin inhibits aortic valve calcification and preserves valve function in hypercholesterolemic mice. PLoS One 2013;8:e65201.
• Mohler ER, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS. Bone formation and inflammation in cardiac valves. Circulation 2001;103:1522-8.
• Lis GJ, Czubek U, Jasinska M, Jasek E, Loboda A, Dulak J, et al. Elevated serum osteoprotegerin is associated with decreased osteoclastic differentiation in stenotic aortic valves. J Physiol Pharmacol 2014;65:377-82.
• Zannettino AC, Holding CA, Diamond P, Atkins GJ, Kostakis P, Farrugia A, et al. Osteoprotegerin (OPG) is localized to the Weibel Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol 2005;204:714-23.
• Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, Smith C, et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 2008;51:627-33.
• Omland T, Drazner MH, Ueland T, Abedin M, Murphy SA, Aukrust P, et al. Plasma osteoprotegerin levels in the general population relation to indices of left ventricular structure and function. Hypertension 2007;49:1392-8.
• Guldiken B, Guldiken S, Turgut B, Turgut N, Demir M, Celik Y, et al. Serum osteoprotegerin levels in patients with acute atherothrombotic stroke and lacunar infarct. Thromb Res 2007;120:511-6.
• Üstündağ M, Orak M, Güloğlu C, Tamam Y, Sayhan MB, Kale E. The role of serum osteoprotegerin and S-100 protein levels in patients with acute ischaemic stroke: determination of stroke subtype, severity and mortality. J Int Med Res 2011;39:780- 9.
• Nybo M, Johnsen SP, Dethlefsen C, Overvad K, Tionneland A, Jorgensen JO, et al. Lack of observed association between high plasma osteoprotegerin concentrations and ischemic stroke risk in a healthy population. Clin Chem 2008;54:1969-74.
• Kuller LH, Shemanski L, Psaty BM, Borhani NO, Gardin J, Haan MN, et al. Subclinical disease as an independent risk factor for cardiovascular disease. Circulation 1995;92:720-6.
• Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intimamedia thickness and risk of stroke and myocardial infarction. The Rotterdam Study. Circulation 1997;96:1432-7.
• Mogelvang R, Haahr-Pedersen S, Bjerre M, Frystyk J, Iversen A, Galatius S, et al. Osteoprotegerin improves risk detection by traditional cardiovascular risk factors and hsCRP. Heart 2013;99:106-10.
• Akinci B, Demir T, Celtik A, Baris M, Yener S, Ozcan MA, et al. Serum osteoprotegerin is associated with carotid intima media thickness in women with previous gestational diabetes. Diabetes Res Clin Pract 2008;82:172-8.
• Oğuz D, Ünal HÜ, Eroğlu H, Gülmez O, Çevik H, Altun A. Aortic flow propagation velocity, epicardial fat thickness, and osteoprotegerin level to predict subclinical atherosclerosis in patients with nonalcoholic fatty liver disease. Anatol J Cardiol 2016;16:974-9.
• Esteghamati A, Aflatoonian M, Red MV, Mazaheri T, Mousavizadeh M, Nakhjavani M, et al. Association of osteoprotegerin with peripheral artery disease in patients with type 2 diabetes. Arch Cardiovasc Dis 2015;108:412-9.
• Lee CJ, Wang JH, Chen ML, Yang CF, Chen YC, Hsu BG. Serum osteoprotegerin is associated with arterial stiffness assessed according to the cardio-ankle vascular index in hypertensive patients. J Atheroscler Thromb 2015;22:304-12.
• Ziegler S, Kudlacek S, Luger A, Minar E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 2005;182:175-80.
• Zauli G, Corrallini F, Bossi F, Fischetti F, Durigutto P, Celeghini C, et al. Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 2007;15;110:536-43.
• Aksu F, Ozçelik F, Kunduracilar H, Barutçu A, Yel M, Umit EG, et al. The relation between the levels of osteoprotegerin and the degree of coronary artery disease in patients with acute coronary syndrome and stable angina pectoris. Kardiol Pol 2014;72:34-41.
• Luo ZR, Zheng WX, Huang MF, Chen H, Wang ZQ. A study of relationship between dialectical classification according to traditional Chinese medicine of acute coronary syndrome with serum osteoprotegerin and its ligands. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2013;25:673-6.
• Jansson AM, Hartford M, Omland T, Karlsson T, Karlsson T, Lindmarker P, Herlitz J. Multimarker risk assessment including osteoprotegerin and CXCL 16 in acute coronary syndromes. Arterioscler Thromb Vasc Biol 2012;32;3041-9.
• Pedersen S, Mogelvang R, Bjerre M, Frystyk J, Flyvbjerg A, Galatius S, et al. Osteoprotegerin predicts long-term outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Cardiology 2012;123:31-8.
• Morena M, Jaussent I, Dupuy AM, Bargnoux AS, Kuster N, Chenine L, et al. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol Dial Transplant 2015;30:1345-56.
• Morena M, Dupuy AM, Jaussent I, Vernhet H, Gahide G, Klouche K, et al. A cutoff value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients. Nephrol Dial Transplant 2009;24:3389-97.
• Nascimento MM, Hayashi SY, Riella MC, Lindholm B. Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stage 3 to 5 chronic kidney disease. Braz J Med Biol Res 2014;47:995- 1002.
• Altun A, Ugur Altun B, Tatli E. Decreased serum osteoprotegerin levels in patients with cardiac syndrome X. J Endocrinol Invest 2004;27:839-43.
• Poornima IG, Mackey RH, Buhari AM, Cauley JA, Matthews KA, Kuller LH. Relationship between circulating serum osteoprotegerin and total receptor activator of nuclear κ-β ligand levels, triglycerides, and coronary calcification in postmenopausal women. Menopause 2014;21:702-10.
• Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004;109;2175-80.
• Ghaffari S, Yaghoubi A, Baghernejad R, Sepehrvand N. Sokhanvar S, Haghjou AG. The value of serum osteoprotegerin levels in patients with angına like chest pain undergoing diagnostic coronary angiography. Cardiol J 2013;20:261-7.
• Anand DV, Lahiri A, Lim E, Hopkins D, Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006;47:1850-7.
• Dhore CR, Cleutjens JP, Lutgens E, Cleutjens KB, Geusens PP, Kitslaar PJ, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001;21:1998-2003.
• Schoppet M, Al-Fakhri N, Franke FE, Katz N, Barth PJ, Maisch B, et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor KappaB ligand in mönckeberg’s sclerosis and atherosclerosis. J Clin Endocrinol Metab 2004;89:4104-12.
• Chapman I. Anatomic and clinical significance of calcification of the aortic knob visualized radiographically. Am J Cardiol 1960;6:281-6.
• Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 2004;291:210-5.
• Price PA, June HH, Buckley JR, Williamson MK. Osteoprotegerin inhibits artery calcification Induced by warfarin and by Vitamin D. Arterioscler Thromb Vasc Biol 2001;21:1610-6.
• Bekker PJ, Holloway D, Nakanishi A, Arrighi HM, leese PT, Dunstan CR. OPG the effect of a single dose of osteoprotegerin in postmenopausal women. Miner Res 2001;16:348-60.
• Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999;140:4367-70.
• Arrighi H, Khosla S, Melton LJ, Riggs B, Bekker P, Dunstan CR. The relationship between circulating osteoprotegerin and estrogen in postmenopausal women. J Bone Miner Res 2000;15:344.
• Persy V, D’Haese P. Vascular calcification and bone disease: the calcification paradox. Trends Mol Med 2009;15:405-16.
• Victor RG, Haley RW, Willett DL, Peshock RM, Vaeth PC, Leonard D, et al. The Dallas Heart Study: A population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol 2004;93:1473-80.
• Arrighi HM, Hsieh A, Wong H, et al. Osteoprotegerin serum levels in healthy volunteers. J Bone Miner Res 1998;14:518-27.
• Khosla S, Arrighi HM, Melton LJ, Atkinson EJ, O’Fallon WM, Dunstan C, et al. Correlates of osteoprotegerin levels in women and men. Osteoporos Int 2002;13:394- 9.
• Kazama JJ, Shigematsu T, Yano K, Tsuda E, Mitura M, Iwasaki W, et al. Increased circulating levels of osteoclastogenesis-inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 2002;39:525-32.
• Knudsen ST, Foss CH, Poulsen PL, Anderson NH, Morgensen CE, Rasmussen LM. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 2003;149:39-42.
• Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 2001;86:3162-5.
• Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003;88:1024-8.
• Kazama JJ, Kato H, Sato T, Shigematsu T, Fukagava M, Iwasaki Y, et al. Circulating osteoprotegerin is not removed through haemodialysis membrane. Nephrol Dial Transplant 2002;17:1860-1.
• Ashley DT, O'Sullivan EP, Davenport C, Devlin N, Crowley RK, McCaffrey N, et al. Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects. Metabolism 2011;60:994-1000.
• Ishida A, Fujita N, Kitazava R, Tsuruo T. Transforming growth factor-beta induces expression of receptor activator of NF-kappa B ligand in vascular endothelial cells derived from bone. J Biol Chem 2002;277:26217-24.
• Fu M, Zhang J, Lin Yq Yq, Zhu X, Wilson TM, Chen YE. Activation of peroxisome proliferator-activated receptor gamma inhibits osteoprotegerin gene expression in human aortic smooth muscle cells. Biochem Biophys Res Commun 2002;294:597- 601.
• Zhang J, Fu M, Myles D, Zhu X, Du J, Cao X, et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett 2002;521:180-4.
• Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
• Yun TJ, Chaudhary PM, Shu GL, Frazer JK, Ewings MK, Schwartz SM, et al. OPG/ FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is upregulated by ligating CD40. J Immunol 1998;161:6113-21.
• Yamaguchi K, Kinosaki M, Goto M, Kobayashi F, Tsuda E, Morinaga T, et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem 1998;273:5117-23.
• Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med (Berl) 2001;79:243- 53.
• Xi L, Cao H, Zhu J, Roe OD, Li M, Wu Y, et al. OPG/RANK/RANKL axis in stabilization of spontaneously restored sinus rhythm in permanent atrial fibrillation patients after mitral valve surgery. Cardiology 2013;124:18-24.
• Ueland T, Yndestad A, Oie E, Florhormen G,Halvorsen B, Frøland SS, et al. Dysregulated osteoprotegerin/ RANK ligand/ RANK axis in clinical and experimental heart failure. Circulation 2005;111:2461-8.
• Browner WS, Lul LY, Cumming SR. Association of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clinic Endocrinol Metab 2001;86:631-7.
• Uyama O, Yoshimoto Y, Yamamoto Y, Kawai A. Bone changes and carotid atherosclerosis in postmenopausal women. Stroke 1997;28:1730-2.
• Jono S, Ikari Y, Shioi A, Mori K, Miki T, Haran K, et al. Serum osteoprotegerin levels are associated with presence and severity of coronary artery disease. Circulation 2002;106:1192-4.
• Lieb W, Gona P, Larson MG, Massaro JM, Lipinska I, Keaney JF Jr. Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol 2010;30:1849- 54.
• Malyankar UM, Scantena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem 2000;275:20959-62.
• Hofbauer LC, Shui C, Riggs BL, Dunstan CR, Spelsberg TC, O’Brein T, et al. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 2001;280:334-9.
• Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin. Paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002;22:549-53.
• Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-8.
• Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
• Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T, et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005;52:3045-53.
• Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408-15.
• Arroyo-Espliguero R, Avanzas P, Cosín-Sales J, Aldama G, Pizzi C, Kaski JC. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J 2004;25:401-8.
• Yeboah J, Erbel R, Delaney JC, Nance R, Guo M, Bertoni AG, et al. Development of a new diabetes risk prediction tool for incident coronary heart disease events: the MultiEthnic Study of Atherosclerosis and the Heinz Nixdorf Recall Study. Atherosclerosis 2014;236:411-7.
• Lopez ADM, CD, Ezzati M, Jamison DT, Murray CJ. Global Burden of Disease and Risk Factors: Disease Control Priorities Project. New York, NY: World Bank and Oxford University Press; 2006.